Additionally, SMAD7 can negatively regulate the function of TGF-β receptor I (TBRI), but it is significantly down-expressed in the CD34+ cells in MDS, resulting in the enhancement of TGF-β signaling. This evidence concerns the gene TGFB1 and myelodysplastic syndrome.